Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children - Vivos Therapeutics ( NASDAQ:VVOS )

2 days ago

On Wednesday, the FDA granted 510 ( k ) clearance to Vivos Therapeutics, Inc.'s VVOS flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea ( OSA ) and snoring in children.

Ticker	Sentiment	Impact
VVOS	Neutral	29 %